The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes
| Autor: | Andreas Meinke, Wolfgang Schüler, Pär Comstedt, Urban Lundberg |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Serotype Bacterial Diseases Physiology lcsh:Medicine Booster dose Pathology and Laboratory Medicine Biochemistry Mice Lyme disease Immune Physiology Medicine and Health Sciences Enzyme-Linked Immunoassays lcsh:Science Lyme Disease Mice Inbred C3H Vaccines Multidisciplinary Immune System Proteins Spirochetes Antibody titer Animal Models Antibodies Bacterial Bacterial Pathogens Body Fluids Infectious Diseases Blood Experimental Organism Systems Medical Microbiology Antigens Surface Bacterial Vaccines Antibody Pathogens Anatomy Bacterial Outer Membrane Proteins Research Article Borrelia Burgdorferi Infectious Disease Control Lipoproteins 030106 microbiology Immunology Mouse Models Biology Serogroup Research and Analysis Methods complex mixtures Microbiology Antibodies 03 medical and health sciences Model Organisms Antigen Borrelia burgdorferi Group Immunity medicine Animals Borrelia burgdorferi Immunoassays Microbial Pathogens Bacteria Borrelia lcsh:R Organisms Lyme Disease Vaccines Biology and Life Sciences Proteins Blood Serum medicine.disease biology.organism_classification bacterial infections and mycoses Virology Borrelia Infection 030104 developmental biology biology.protein Immunologic Techniques bacteria lcsh:Q Immune Serum |
| Zdroj: | PLoS ONE PLoS ONE, Vol 12, Iss 9, p e0184357 (2017) |
| ISSN: | 1932-6203 |
| Popis: | We have previously shown that the Outer surface protein A (OspA) based Lyme borreliosis vaccine VLA15 induces protective immunity in mice. Herein, we report the induction of protective immunity by VLA15 with mouse models using ticks infected with B. burgdorferi (OspA serotype 1), B. afzelii (OspA serotype 2) and B. bavariensis (OspA serotype 4) or with in vitro grown B. garinii (OspA serotype 5 and 6) for challenge. For B. garinii (OspA serotype 3), we have developed a growth inhibition assay using chicken complement and functional antibodies targeting B. garinii (OspA serotype 3) could be demonstrated after immunization with VLA15. Furthermore, following three priming immunizations, a booster dose was administered five months later and the induction of immunological memory could be confirmed. Thus, the antibody titers after the booster dose were increased considerably compared to those after primary immunization. In addition, the half-lives of anti-OspA serotype specific antibodies after administration of the booster immunization were longer than after primary immunization. Taken together, we could show that VLA15 induced protection in mice against challenge with four different clinically relevant Borrelia species (B. burgdorferi, B. afzelii, B. garinii and B. bavariensis) expressing five of the six OspA serotypes included in the vaccine. The protection data is supported by functional assays showing efficacy against spirochetes expressing any of the six OspA serotypes (1 to 6). To our knowledge, this is the first time a Lyme borreliosis vaccine has been able to demonstrate such broad protection in preclinical studies. These new data provide further promise for the clinical development of VLA15 and supports our efforts to provide a new Lyme borreliosis vaccine available for global use. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|